BG61728B1 - 2,9-дизаместени пурин-6-они - Google Patents

2,9-дизаместени пурин-6-они Download PDF

Info

Publication number
BG61728B1
BG61728B1 BG100292A BG10029296A BG61728B1 BG 61728 B1 BG61728 B1 BG 61728B1 BG 100292 A BG100292 A BG 100292A BG 10029296 A BG10029296 A BG 10029296A BG 61728 B1 BG61728 B1 BG 61728B1
Authority
BG
Bulgaria
Prior art keywords
carbon atoms
straight
phenyl
substituted
branched chain
Prior art date
Application number
BG100292A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG100292A (bg
Inventor
Ulrich Niewoehner
Erwin Bischoff
Helmuth Schuetz
Elisabeth Perzborn
Matthias Schramm
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BG100292A publication Critical patent/BG100292A/bg
Publication of BG61728B1 publication Critical patent/BG61728B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG100292A 1995-01-19 1996-01-18 2,9-дизаместени пурин-6-они BG61728B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19501482A DE19501482A1 (de) 1995-01-19 1995-01-19 2,9-disubstituierte Purin-6-one

Publications (2)

Publication Number Publication Date
BG100292A BG100292A (bg) 1996-07-31
BG61728B1 true BG61728B1 (bg) 1998-04-30

Family

ID=7751830

Family Applications (1)

Application Number Title Priority Date Filing Date
BG100292A BG61728B1 (bg) 1995-01-19 1996-01-18 2,9-дизаместени пурин-6-они

Country Status (31)

Country Link
US (1) US5861404A (pt)
EP (1) EP0722944A1 (pt)
JP (1) JPH08231545A (pt)
KR (1) KR960029334A (pt)
CN (1) CN1135485A (pt)
AR (1) AR002953A1 (pt)
AU (1) AU4097996A (pt)
BG (1) BG61728B1 (pt)
BR (1) BR9600147A (pt)
CA (1) CA2167353A1 (pt)
CO (1) CO4700523A1 (pt)
CZ (1) CZ16696A3 (pt)
DE (1) DE19501482A1 (pt)
EE (1) EE9600018A (pt)
FI (1) FI960225A (pt)
HR (1) HRP960007A2 (pt)
HU (1) HUP9600106A3 (pt)
IL (1) IL116769A (pt)
MA (1) MA23778A1 (pt)
NO (1) NO960223L (pt)
NZ (1) NZ280830A (pt)
PE (1) PE64996A1 (pt)
PL (1) PL312354A1 (pt)
SG (1) SG50401A1 (pt)
SK (1) SK8096A3 (pt)
SV (1) SV1996000006A (pt)
TN (2) TNSN96007A1 (pt)
TR (1) TR199600028A2 (pt)
TW (1) TW314519B (pt)
YU (1) YU1396A (pt)
ZA (1) ZA96398B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19529102A1 (de) * 1995-08-08 1997-02-13 Kummer Horst Dieter Verwendung von PDE-Inhibitoren bei der Behandlung von Harnblasenerkrankungen
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
NZ502752A (en) * 1997-07-15 2001-01-26 Japan Energy Corp Purine derivatives and their use in the treatment of nephritis
CN1130363C (zh) 1997-11-12 2003-12-10 三菱化学株式会社 嘌呤衍生物以及含有其作为有效成分的药物
DE69815554T2 (de) * 1998-01-05 2004-05-06 Eisai Co., Ltd. Purinderivate und antagonisten des adenosin-a2-rezeptors, welche zur vorsorge oder heilung von diabetes dienen
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
ATE254616T1 (de) 1999-05-11 2003-12-15 Mitsubishi Chem Corp Dihydrat eines purinderivates, medikamente die dieses als aktiven wirkstoff enthalten und zwischenprodukte zu dessen herstellung
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
AU2001284444B2 (en) * 2000-09-06 2006-05-25 Mitsubishi Tanabe Pharma Corporation Preparations for oral administration
DE60236850D1 (de) * 2001-02-15 2010-08-12 Mitsubishi Tanabe Pharma Corp Tabletten, die in der mundhöhle schnell zerfallen
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
CN102742513A (zh) * 2012-07-17 2012-10-24 南京熊猫机电制造有限公司 一种喂食栏装置
EP3157520B1 (en) 2014-06-23 2019-09-04 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
CN114072407A (zh) 2019-04-02 2022-02-18 阿里戈斯治疗公司 靶向prmt5的化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451478A (en) * 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
IL76546A (en) * 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
HUP9600106A2 (en) 1997-05-28
BR9600147A (pt) 1998-01-06
NO960223D0 (no) 1996-01-18
NZ280830A (en) 1998-04-27
KR960029334A (ko) 1996-08-17
DE19501482A1 (de) 1996-07-25
TW314519B (pt) 1997-09-01
FI960225A0 (fi) 1996-01-17
PE64996A1 (es) 1997-03-09
TNSN96006A1 (fr) 2005-03-15
SV1996000006A (es) 1996-10-29
AU4097996A (en) 1996-07-25
SG50401A1 (en) 1998-07-20
IL116769A (en) 1998-12-06
BG100292A (bg) 1996-07-31
IL116769A0 (en) 1996-05-14
CA2167353A1 (en) 1996-07-20
JPH08231545A (ja) 1996-09-10
YU1396A (sh) 1999-03-04
TNSN96007A1 (fr) 2005-03-15
NO960223L (no) 1996-07-22
ZA96398B (en) 1996-08-28
AR002953A1 (es) 1998-05-27
US5861404A (en) 1999-01-19
TR199600028A2 (tr) 1996-08-21
CO4700523A1 (es) 1998-12-29
PL312354A1 (en) 1996-07-22
EE9600018A (et) 1996-08-15
HRP960007A2 (en) 1998-02-28
FI960225A (fi) 1996-07-20
HUP9600106A3 (en) 1998-04-28
CN1135485A (zh) 1996-11-13
HU9600106D0 (en) 1996-03-28
SK8096A3 (en) 1996-08-07
CZ16696A3 (en) 1996-08-14
MA23778A1 (fr) 1996-10-01
EP0722944A1 (de) 1996-07-24

Similar Documents

Publication Publication Date Title
BG61728B1 (bg) 2,9-дизаместени пурин-6-они
KR101491938B1 (ko) Ｉｐ 수용체 효능제 헤테로시클릭 화합물
AU704102B2 (en) 2,8-disubstituted quinazolinones
AU727615B2 (en) 1,5-dihydro-pyrazolo(3,4-d)-pyrimidinone derivatives
AU720305B2 (en) Purin-6-one derivatives
EP2802589B1 (en) Fused pyrroles as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
CZ374992A3 (en) Polycyclic guanine derivatives
EP2802583A1 (en) Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
NZ336124A (en) 5-aralkyl or (aryl, heteroaryl or heteroarylalkyl) substituted pyrrolo[3,4-d]pyrimidinone derivatives and medicaments
KR20090106633A (ko) ＰＤＥ5 억제제로서 유용한 6-벤질-2,3,4,7-테트라히드로-인돌로[2,3-ｃ]퀴놀린 화합물
BG61729B1 (bg) 9-заместени-2-(2-норм-алкоксифенил)пурин-6-они
EP0183848B1 (en) Polyazaheterocyclic derivatives, process for their preparation, and pharmaceutical composition
JPH04221384A (ja) 選択的アデノシン受容体アゴニスト及びアンタゴニスト
WO1993017023A1 (fr) Derives de pyrazolopyrimidines antagonistes des recepteurs a l'angiotensine ii
EP4029858A1 (en) Pyrimidine compound and preparation method therefor
US6458792B1 (en) Compounds
US6949652B2 (en) Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine
EP2885297B1 (fr) Pyrido[3,2-d]pyrimidines trisubstituées, leurs procédés de préparation et leurs utilisations en thérapeutique
KR20030065519A (ko) 신규 피리딘 치환 피라졸로피리딘 유도체
WO2009037302A1 (en) 5-substituted-1, 4-benz0diazepines as phosphodiesterase inhibitors
JPH11269071A (ja) 糸球体疾患の予防及び治療剤